SSY Revenue May Rebound in 2026 On New Drug Tender wins -- Market Talk

Dow Jones04-07

0019 GMT - SSY is expected to see revenue growth from this year onward, driven by recent wins in the 11th round of China's centralized drug procurement program, Citi analyst John Yung says. While 2025 revenue and net profit fell on lower average selling prices, including for IV solutions, management expects higher sales volumes this year. Past contract renewals also came at higher tender prices, boosting revenue. However, Citi cuts the stock's target price to 4.0 Hong Kong dollars from HK$5.0 to reflect the weak 2025 results but maintains a buy rating. The stock was last closed at HK$2.50. (venkat.pr@wsj.com)

(END) Dow Jones Newswires

April 06, 2026 20:19 ET (00:19 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2625598854?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-07 08:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2625598854","market":"sg","top_or_hot":-1,"title":"SSY Revenue May Rebound in 2026 On New Drug Tender wins -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0019 GMT - SSY is expected to see revenue growth from this year onward, driven by recent wins in the 11th round of China's centralized drug procurement program, Citi analyst John Yung says. While 2025 revenue and net profit fell on lower average selling prices, including for IV solutions, management expects higher sales volumes this year. Past contract renewals also came at higher tender prices, boosting revenue. However, Citi cuts the stock's target price to 4.0 Hong Kong dollars from HK$5.0 to reflect the weak 2025 results but maintains a buy rating. The stock was last closed at HK$2.50. (venkat.pr@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 06, 2026 20:19 ET (00:19 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SSY Revenue May Rebound in 2026 On New Drug Tender wins -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSSY Revenue May Rebound in 2026 On New Drug Tender wins -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-07 08:19</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0019 GMT - SSY is expected to see revenue growth from this year onward, driven by recent wins in the 11th round of China's centralized drug procurement program, Citi analyst John Yung says. While 2025 revenue and net profit fell on lower average selling prices, including for IV solutions, management expects higher sales volumes this year. Past contract renewals also came at higher tender prices, boosting revenue. However, Citi cuts the stock's target price to 4.0 Hong Kong dollars from HK$5.0 to reflect the weak 2025 results but maintains a buy rating. The stock was last closed at HK$2.50. (venkat.pr@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 06, 2026 20:19 ET (00:19 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SSY","symbol_name":"Sunlink Health Systems Inc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2625598854","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2625598854","pubTimestamp":1775521140,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0019 GMT - SSY is expected to see revenue growth from this year onward, driven by recent wins in the 11th round of China's centralized drug procurement program, Citi analyst John Yung says. While 2025 revenue and net profit fell on lower average selling prices, including for IV solutions, management expects higher sales volumes this year. Past contract renewals also came at higher tender prices, boosting revenue. However, Citi cuts the stock's target price to 4.0 Hong Kong dollars from HK$5.0 to reflect the weak 2025 results but maintains a buy rating. The stock was last closed at HK$2.50. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"SSY":"Sunlink Health Systems Inc"},"translate_title":"由于新药中标，SSY收入可能在2026年反弹——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SSY":1.5},"content_text":"0019 GMT - SSY is expected to see revenue growth from this year onward, driven by recent wins in the 11th round of China's centralized drug procurement program, Citi analyst John Yung says. While 2025 revenue and net profit fell on lower average selling prices, including for IV solutions, management expects higher sales volumes this year. Past contract renewals also came at higher tender prices, boosting revenue. However, Citi cuts the stock's target price to 4.0 Hong Kong dollars from HK$5.0 to reflect the weak 2025 results but maintains a buy rating. The stock was last closed at HK$2.50. (venkat.pr@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 06, 2026 20:19 ET (00:19 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2625598854","isCrawlerRequest":true}